Metformin for slowing aging
The trial meant to settle this has never enrolled anyone. The question that has been tested twice is whether metformin blunts what exercise does.
The trial that was going to settle this has never started
Metformin is the most widely taken longevity drug in the world, and the study designed to find out whether it is one has not enrolled a single participant.
TAME — Targeting Aging with Metformin — was conceived over a decade ago as the trial that would test whether metformin delays age-related disease in people who do not have diabetes. As of 2026 it has not launched, is not recruiting, and has no sites listed. It needs roughly $75 million and has never secured it.1
The reason is worth stating plainly, because it is not a scientific one. Metformin is off-patent and costs a few pounds a month. There is no molecule to commercialise at the end of a successful trial, so no company has reason to fund one, and TAME has depended on philanthropy for its entire existence.
A question can remain open for fifteen years because nobody stands to profit from closing it. That is a fact about the incentives around evidence, not about metformin.
So the headline claim on this page — that metformin slows ageing in people without diabetes — has zero completed qualifying trials. Not weak evidence. None.
Where the belief came from
The case rests largely on observational work reporting that people with diabetes taking metformin outlived matched controls without diabetes. It is a striking finding and it is the single most cited justification for taking the drug.
It is also the kind of comparison our rubric treats with the most caution. People prescribed metformin differ from people who are not in ways no statistical adjustment fully captures — how early they were diagnosed, how engaged they are with healthcare, what else they take, what they were prescribed instead. Observational data can generate this hypothesis. It cannot grade it.
Under our scale, a claim with no completed randomised trial in humans is Preliminary, no matter how much non-randomised data surrounds it.
The finding nobody puts on the label
There is one metformin-and-ageing question that has been tested properly, twice, by different groups. It is not the one people take it for, and the answer runs against the drug.
Metformin plus exercise training in older adults
Two randomised, double-blind, placebo-controlled trials, run by different groups, in different training modalities, reaching the same conclusion: metformin blunted the adaptations that exercise produced. In the aerobic trial the drug cut the VO₂max improvement roughly in half.2 In the multicentre resistance trial the placebo group built more muscle than the metformin group.3
Set the two claims side by side. The reason people take metformin for longevity has never been tested in a randomised trial. The effect that has been replicated in randomised trials is that it interferes with the single intervention most reliably associated with living longer.
That is not an argument against metformin for diabetes, where it is an excellent drug with decades of outcome data. It is an argument about taking it while healthy, in the hope of ageing more slowly, alongside training.
The two claims, graded
The second sits at two dots only because the two trials together enrolled 147 people, and our scale requires 200 for Moderate. It clears every other test for that grade — two randomised placebo-controlled trials, two independent groups, consistent direction. Fifty-three more participants would move it, which puts it on the watchlist.
Safety and unknowns
-
Gastrointestinal effects
Nausea, diarrhoea and abdominal discomfort are common, dose-related, and the usual reason people stop. Extended-release formulations reduce but do not remove them.
-
Vitamin B12
Long-term metformin reduces B12 absorption, and deficiency can present as neuropathy that is easy to attribute to ageing instead. Periodic testing is standard practice in diabetes care and is routinely skipped by people taking it off-label.
-
Lactic acidosis
Rare but serious, and the reason metformin is contraindicated in significant kidney impairment. Risk rises with conditions that reduce clearance.
-
Exercise interaction
The replicated finding above. If training is part of why you are taking it, this is the most relevant thing on this page.
-
Long-term use in healthy people
Unstudied for the purpose. The safety record is drawn from decades of use in diabetes, which is a different population with a different baseline risk.
How the grade was reached
Evidence strength — Preliminary, criteria checked
One dot is not a judgement that metformin fails to slow ageing. It is a statement that after fifteen years of discussion, nobody has run the trial.
Bottom line
Metformin might slow ageing. The trial designed to find out has never started, is not recruiting, and needs about $75 million that no one will supply because the drug is generic. That is the entire state of the evidence for the claim.
Meanwhile, the best-tested question about metformin in healthy older adults is whether it interferes with exercise adaptation, and two randomised trials in different training modalities both found that it does.
For diabetes it remains an excellent, well-evidenced drug. For slowing ageing in a healthy person who trains, the evidence currently points the other way.
Sources
- American Federation for Aging Research. TAME — Targeting Aging with Metformin. Trial status and funding requirement; as of 2026 not launched and not recruiting. afar.org/tame-trial
- Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. 53 adults, 12 weeks. PMID 30548390. pubmed.ncbi.nlm.nih.gov/30548390
- Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial. Aging Cell. 2019;18(6):e13039. 94 adults aged 65+, 14 weeks, multicentre. PMID 31557380. pubmed.ncbi.nlm.nih.gov/31557380
- Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty (MET-PREVENT): a double-blind, randomised, placebo-controlled trial. The Lancet Healthy Longevity. 2025. thelancet.com
- A randomized placebo-controlled trial of metformin for frailty prevention in older adults. ncbi.nlm.nih.gov/PMC8681623
- Metformin alters skeletal muscle transcriptome adaptations to resistance training in older adults. Aging. Companion analysis to the MASTERS trial. ncbi.nlm.nih.gov/PMC7655218
